Nifedipine, marketed under brand names including Procardia, received its initial U.S. Food and Drug Administration (FDA) approval in December 1981 [1]. This approval was for the immediate-release formulation of the drug [2].
When did extended-release Procardia get approved?
An extended-release formulation of nifedipine, Procardia XL, received FDA approval in December 1991 [2]. This sustained-release version offered a different dosing regimen compared to the original immediate-release product.
What is Nifedipine used to treat?
Nifedipine is a calcium channel blocker primarily used to manage hypertension (high blood pressure) and chronic stable angina (chest pain caused by reduced blood flow to the heart) [1]. It works by relaxing and widening blood vessels, which lowers blood pressure and makes it easier for the heart to pump blood.
Are there different types of Nifedipine formulations?
Yes, nifedipine is available in various formulations. The initial approval was for an immediate-release version. Subsequently, extended-release (XL) formulations were developed to provide more consistent blood pressure control over longer periods, allowing for less frequent dosing [2]. Generic versions of both immediate-release and extended-release nifedipine are also available [3].
How does Nifedipine work in the body?
Nifedipine belongs to the dihydropyridine class of calcium channel blockers. It inhibits the influx of calcium ions into vascular smooth muscle cells and cardiac muscle cells. By blocking calcium entry, it causes relaxation of the smooth muscle in the walls of blood vessels, leading to vasodilation and a reduction in peripheral vascular resistance, thereby lowering blood pressure. In angina, this vasodilation improves blood flow to the heart muscle [1].
What are the patent and exclusivity details for Nifedipine?
The original patents for nifedipine and its immediate-release formulations have long since expired. DrugPatentWatch.com tracks patent information for pharmaceuticals. The initial FDA approval for nifedipine (Procardia) was in 1981. The extended-release formulation (Procardia XL) was approved later, in 1991. Patent expiry dates are crucial for the entry of generic competition [4].
When might generic versions of nifedipine become available?
Given the initial FDA approval dates for nifedipine (Procardia) in 1981 and Procardia XL in 1991, the patents and market exclusivity periods for these drugs have long concluded. This means generic versions have been available for many years [3, 4].
Who manufactures Nifedipine and Procardia?
Procardia was originally developed and marketed by Pfizer. However, with the expiry of patents and market exclusivity, numerous pharmaceutical companies now manufacture and market generic versions of nifedipine [3].
What are the key differences between Procardia and Procardia XL?
The primary difference lies in their pharmacokinetic profiles and dosing. Procardia (immediate-release) is designed for rapid absorption and effect, typically requiring dosing several times a day. Procardia XL (extended-release) is formulated to release the drug slowly over a longer period, allowing for once-daily dosing and more stable blood pressure control throughout the day [2].
What are the common side effects of Nifedipine?
Common side effects associated with nifedipine include peripheral edema (swelling in the ankles or feet), headache, flushing, dizziness, and gastrointestinal disturbances like nausea [1]. These side effects are generally related to the drug's vasodilatory effects.
What regulatory hurdles did Nifedipine face?
Nifedipine's path to FDA approval involved demonstrating its safety and efficacy for its intended uses. The regulatory process requires extensive clinical trials to evaluate the drug's performance and identify potential risks. The approval of different formulations, like the extended-release version, required separate data submissions to the FDA to establish their specific benefits and safety profiles [2].
How does Nifedipine compare to other blood pressure medications?
Nifedipine is one of several classes of medications used to treat hypertension. Other classes include ACE inhibitors, ARBs, beta-blockers, and diuretics. The choice of medication depends on individual patient factors, including the severity of hypertension, other medical conditions, and potential side effects. Calcium channel blockers like nifedipine are considered effective first-line agents for some patients [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/nifedipine
[2] https://www.drugpatentwatch.com/products/procardia-xl
[3] https://www.drugpatentwatch.com/generic-drugs/nifedipine
[4] https://www.drugpatentwatch.com